Citations

Clear

35 citation(s) found for "Smith, Benjamin J".

Widespread Loss of Heterozygosity and Endoreduplication in Odontogenic Myxoma
Stojanov, Ivan J. , Dababneh, Melad N., Cracolici, Vincent, Qureshi, Sana, Hattery, Travis , Chen, Mark , Smith, Benjamin F. , O’Neill, Diane, Wolbert, Matthew, Schneider, Keith M., Shurtleff, Sheila, Astbury, Caroline , Geiersbach, Katherine B. , Woo, Sook-Bin, Fritchie, Karen, Weber, Grace E. , Dermawan, Josephine K., Dababneh, Melad , Cracolici, Vincent , O'Neill, Diane H., Schneider, Keith M., Shurtleff, Sheila A., Woo, Sook‐Bin , Fritchie, Karen, Dermawan, Josephine K.

Mayo Clinic

American Journal of Surgical Pathology | September 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/pas.0000000000002616 | PMID 42745350 Get It

Odontogenic myxoma (OM) is an uncommon, locally aggressive odontogenic neoplasm with characteristic histologic and clinico-radiographic features but with potential for histologic overlap with other odontogenic and non-odontogenic entities and a non-specific immunoprofile. Widespread loss of heterozygosity (LOH) has been recently described in rare cases of OM. The aim of this study was to determine whether widespread LOH represents a recurrent molecular signature that can be leveraged for clinical decision-making. Allele-specific copy number variation data from chromosomal microarray were generated from 7 OM, comprising a combined prospective and retrospective cohort. Four tumors arose in the mandible and 3 in the maxilla in patients ranging in age from 18 to 94 years (median: 44), with tumor size ranging from 2.2 to 13.0 cm. Variable amounts of fibrous stroma (odontogenic “fibromyxoma”) were present in 4/7 OM, and hypercellularity not typically appreciated in conventional OM was present in 3/7 cases. All OM (7/7) demonstrated widespread LOH, with 5 cases showing a near-haploid/low hypodiploid genomes (multiple monosomies) and 2 cases showing evidence of pseudo-hyperdiploidy due to probable endoreduplication. Both pseudo-hyperdiploid cases were ≥10 cm in size; 1 represented local recurrence. Chromosomes 1 to 3, 6, 9, 11, 13, 15, and 22 demonstrated LOH in ≥75% of cases (chromosomes 1 to 3, 6, and 9 in 100% of cases), while chromosomes 5, 12, 19, and 20 universally retained heterozygosity. Altogether, widespread LOH is a recurrent event in OM and a novel finding in odontogenic pathology, and allele-specific copy number variation analysis can serve as a diagnostic adjunct in challenging cases.
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
Sherry, Alexander D. , Haymaker, C, Wang, S, Liu, S, Medina-Rosales, Marina Nayeli , Seo, Aaron, Reddy, Jay P. , Mayo, Lauren L., Pant, Shubham , Kovitz, Craig A., Ha, Chul S., Smith, BD, Gomez, Daniel, Cohen, Lorenzo , Tannir, Nizar, Corn, Paul G., Siddiqui, Bilal A. , Ludmir, Ethan B., Tang, Chad , Haymaker, Cara , Liu, Suyu , Haymaker, Cara , Wang, Shuqi , Liu, Suyu , Bathala, Tharakeswara K , Medina-Rosales, Marina N , Reddy, Jay P , Chun, Stephen G , Walker, Gary , Pant, Shubham , Zhao, Dan , Kovitz, Craig A , Smith, Benjamin D , Gomez, Daniel , Cohen, Lorenzo , Koong, Albert C , Reuben, Alexandre , Tannir, Nizar , Tran, Phuoc T , Siddiqui, Bilal A , Subudhi, Sumit Kumar , Msaouel, Pavlos , Ludmir, Ethan B , Tang, Chad , Sherry, Alexander D , Seo, Aaron , Hara, Kieko , Chun, Stephen G. , Mayo, Lauren L. , Zhao, Dan , Ramirez, David Luis , Ha, Chul S. , Corn, Paul Gettys , Msaouel, Pavlos , Ludmir, Ethan B.

Mayo Clinic

Journal of Clinical Oncology | May 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-25-02856 | PMID 42142259 Get It

PURPOSE We tested the hypothesis that adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy improves progression-free survival (PFS) among patients with oligometastatic disease. METHODS EXTEND was a multicenter randomized phase II trial. Patients with 1-5 metastases were randomly assigned to MDT + SOC versus SOC in one of the six baskets (breast, pancreas, kidney, two prostate baskets, and an other basket) with basket-specific stratification and powering. PFS, the primary end point, was prespecified in the per-protocol set within each basket, across all baskets, and across all baskets excluding the prostate baskets. Exploratory end points included circulating tumor DNA (ctDNA) and immune profiling. RESULTS From 2018 through 2023, 521 patients were screened, 350 were randomly assigned, and 334 were analyzed per protocol (MDT + SOC, n = 166; SOC, n = 168). Radiotherapy was used as MDT for 98% of metastases (370/379). Overall, after a median follow-up of 53 months, PFS was improved with MDT + SOC (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.72], P < .001). Similarly, PFS was improved when excluding the prostate baskets (HR, 0.60 [95% CI, 0.40 to 0.89]). Within each basket, PFS superiority was identified for the pancreas, prostate, and other baskets, whereas the breast and kidney baskets were inconclusive. At enrollment, detectable ctDNA correlated with shorter PFS and survival; by contrast, ctDNA clearance 3 months postenrollment correlated with improved survival. MDT + SOC-induced systemic immune activation was most pronounced among baskets demonstrating PFS superiority. CONCLUSION The phase II EXTEND trial supports the addition of MDT to SOC for oligometastatic disease. Histology-specific efficacy signals were identified for phase III testing. Translational insights suggest the potential for optimizing the definition of oligometastasis using ctDNA and point to systemic immune responses as a possible mechanism of benefit from MDT.
Mucus plugs in chronic obstructive pulmonary disease are heterogeneous in size and shape and occur in relatively large airways
Farooqui, Omar, Elicker, Brett M. , Henry, Travis, Hahn, Lewis D. , Kallianos, Kimberly , Han, MeiLan K, Barr, R Graham, Smith, Benjamin M, Comellas, Alejandro P, Bon, Jessica , Hansel, Nadia, Wells, J Michael, Paine, R, Barjaktarevic, I., Schroeder, Joyce , Woodruff, Prescott G, Huang, B J, FAHY, JOHN V., Wells, J. Michael , Comellas, Alejandro P. , Smith, Benjamin M. , Schroeder, Joyce D , Comellas, Alejandro P , Wells, J Michael , Henry, Travis S, Han, MeiLan King , Barr, R. Graham, Smith, Benjamin M., Hansel, Nadia, Barjaktarević, Igor , Woodruff, Prescott G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | January 5, 2026 | Volume: 212 | Issue: 2 | Pages: 268-276

10.1093/ajrccm/aamaf138 | PMID 41738094 Get It

Abstract Rationale Mucus plugs occur in chronic obstructive pulmonary disease (COPD), but little is known about their size and airway location or whether these mucus plug features change as emphysema worsens. Methods Computed tomographic lung scans from 31 participants with COPD from the SubPopulations and InteRmediate Outcomes In COPD Study (SPIROMICS) cohort were analyzed to quantify mucus plug size and airway location and extent of emphysema. Radiologist annotations of mucus plugs were incorporated in an image processing pipeline to generate size and location information. Emphysema was quantified as the percentage of voxels less than -950 Hounsfield units. Measurements and Main Results The length distribution of 563 annotated mucus plugs varied from 2 to 50 mm. The distribution was multimodal, and an 11-mm length defined short (“stubby,” ≤11 mm) and long (“stringy,” &gt;11 mm) plug phenotypes, with stubby plugs being most common (64%). Mucus plugs localized predominantly to airway generations 6 to 9, and their prevalence was highest in lower lobes. On a lobar basis, the mucus plug number decreased as emphysema percentage increased, whereas average mucus plug volume tended to increase. Conclusion COPD is characterized by mucus plugs of varying size and shape, and emphysematous lung regions may be differentially susceptible to formation of these plugs. The location of mucus plugs in segmental and subsegmental airways in COPD makes them amenable to treatment with inhaled medications or bronchoscopy.
Epigenomic study of the lower airway reveals COPD-associated methylation patterns and potential microbiota links
Cao, Sudan , Shrivastav, Abhishek, Bleecker, Eugene R., Madapoosi, Siddharth , Erb‐Downward, John R. , Zein, Joe , Howard, Timothy D. , Hawkins, Gregory A., Barjaktarević, Igor , Bowler, Russell, Barr, Robert, Comellas, Alejandro P. , Cooper, Christopher B. , Hansel, Nadia N. , Hastie, Annette T. , Kanner, Richard E. , Moore, Wendy C. , O’Neal, Wanda K. , Paine, Robert , Smith, Benjamin M. , Hoffman, Eric A. , Meyers, Deborah A. , Woodruff, Prescott G. , Christenson, Stephanie A. , Ortega, Victor E. , Cao, Shuo , Chen, Xianfeng , Barjaktarevic, Igor , Comellas, Alejandro P , Han, MeiLan King , Kim, Victor , Huang, Yvonne J , O'Neal, Wanda K , Hoffman, Eric A , Christenson, Stephanie A , Chen, Xianfeng, Couper, David , Kaner, Robert J. , Martínez, Fernando J. , Curtis, Jeffrey L.

Mayo Clinic

BMJ Open Respiratory Research | December 19, 2025 | Volume: 12 | Issue: 1 | Pages: e003572

10.1136/bmjresp-2025-003572 | PMID 41419234 Get It

Introduction Despite the identification of multiple susceptibility loci by genome-wide association studies (GWAS), considerable chronic obstructive pulmonary disease (COPD) heritability remains unexplained. Aim To identify interaction networks of airway epithelial cell DNA methylation in COPD and further explore potential correlations with airway bacterial composition, as potentially collective regulators of biological pathways influencing COPD severity. Methods Using DNA isolated from bronchial airway brushings of 67 ever-smokers (>20 pack-years) from the SubPopulations and InteRmediate Outcomes Measures in COPD Study (SPIROMICS), we assessed proportion of DNA methylation (β) by epigenome-wide association study (EWAS) and examined associations of differentially methylated CpG probes (DMPs) with risk for moderate-to-severe COPD (N=34) versus absent or mild COPD (N=33). We tested co-methylation modules generated by Weighted Correlation Network Analyses (WGCNA) for associations with moderate-to-severe COPD and with bacterial genus-level relative abundances (16S rRNA sequencing). Results EWAS-identified nominally significant DMPs enriched for lung function GWAS loci. Eigengenes in six WGCNA modules were associated with moderate-to-severe COPD (false discovery rate <0.05). Four of those modules were enriched for forced expiratory volume in 1 s/forced vital capacity GWAS loci, and five overlapped with DMPs from EWAS. Overlapping CpG loci in three COPD-associated modules were adjacent to mucin genes; one had 10 genes highly ranked by connectivity with MUC5B, including important pathway genes: B3GNT6 , DGKI and ITGA8 . CpGs in an independent COPD-associated module showed the most correlations with Rothia , with directionality suggestive of negative associations with moderate-severe COPD. Conclusions Bronchial epithelial DNA methylation modules enriched for lung function GWAS loci associate with COPD severity in SPIROMICS. Potential module relationships to bronchial bacterial composition require further validation.
2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus
Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Hiraki, Linda T. , Aranow, Cynthia , Barnado, April , Broder, Anna , Chowdhary, Vaidehi , Hersh, Aimee O. , Jules, Marimee, Kalunian, Kenneth , Smith, Benjamin J. , Smith, Natalie, Thomas, Asha , Timlin, Homa , Bartels, Christie M. , Cunha, Joanne S., DeQuattro, Kimberly , Gomes, Laís Lopes Almeida , Cuéllar‐Gutiérrez, María C. , Iyer, Priyanka , Johannemann, Andrew, Jorge, April , Kasturi, S.Psi. Taufik , Khawandi, Jana , Legge, Alexandra , Liang, Kimberly P. , Lockwood, Megan M. , Sánchez-Rodríguez, Alain , Turgunbaev, Marat, Williams, Jessica N. , Turner, Amy S. , Aranow, Cynthia , Barnado, April , Brunner, Hermine I , Chong, Benjamin F , Hersh, Aimee O , Rubinstein, Tamar B , Smith, Benjamin J , Wallace, Daniel J , Bartels, Christie M , DeQuattro, Kimberly , Figueroa-Parra, Gabriel , Garg, Shivani , Gomes, Lais Lopes Almeida , Cuéllar-Gutiérrez, María C, Jorge, April , Kasturi, Shanthini , Kawtharany, Hassan , Liang, Kimberly P , Lockwood, Megan M , Sanchez-Rodriguez, Alain , Williams, Jessica N , Turner, Amy S , Duarte-García, Alí , Sammaritano, Lisa R , Askanase, Anca , Bermas, Bonnie , Son, Mary Beth F. , Werth, Victoria P. , Chong, Benjamin F. , Izmirly, Peter , Jules, Marimee, Kamen, Diane L. , Thomas, Asha, Azzam, Muayad , Fava, Andrea , Figueroa‐Parra, Gabriel , Garg, Shivani , Kawtharany, Hassan , Mustafa, Reem A

Mayo Clinic

Arthritis & Rheumatology | November 4, 2025 | Volume: 78 | Issue: 7 | Pages: 1361-1386

10.1002/art.43452 | PMID 41187097 Get It

Objective To provide evidence‐based and expert guidance for the treatment and management of non‐renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline. Methods Clinical questions for treatment and management of SLE were developed in the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were developed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess evidence quality and formulate recommendations. The Voting Panel achieved a consensus of ≥70% agreement on the direction (for or against) and strength (strong or conditional) of each recommendation. Results We present recommendations and ungraded, consensus‐based good practice statements for the treatment and management of SLE that are applicable to pediatric and adult patients. Recommendations emphasize uniform treatment with hydroxychloroquine, limiting duration of glucocorticoid use, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve and maintain control of SLE inflammation (remission or a low level of disease activity), reduce SLE‐related morbidity and mortality, and minimize medication‐related toxicities. Conclusion This guideline presents direction regarding treatment and management of SLE and provides a foundation for well‐informed, shared clinician–patient decision‐making. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each person with SLE.
2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus
Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Hiraki, Linda T. , Aranow, Cynthia , Barnado, April , Broder, Anna , Chowdhary, Vaidehi , Hersh, Aimee O. , Jules, Marimee, Kalunian, Kenneth , Smith, Benjamin J. , Smith, Natalie, Thomas, Asha , Timlin, Homa , Cunha, Joanne S., DeQuattro, Kimberly , Gomes, Laís Lopes Almeida , Iyer, Priyanka , Johannemann, Andrew, Jorge, April , Kasturi, S.Psi. Taufik , Khawandi, Jana , Legge, Alexandra , Liang, Kimberly P. , Lockwood, Megan M. , Sánchez-Rodríguez, Alain , Turgunbaev, Marat, Williams, Jessica N. , Turner, Amy S. , Aranow, Cynthia , Barnado, April , Brunner, Hermine I , Chong, Benjamin F , Hersh, Aimee O , Rubinstein, Tamar B , Smith, Benjamin J , Wallace, Daniel J , Bartels, Christie M , DeQuattro, Kimberly , Figueroa-Parra, Gabriel , Garg, Shivani , Gomes, Lais Lopes Almeida , Cuéllar-Gutiérrez, María C, Jorge, April , Kasturi, Shanthini , Kawtharany, Hassan , Liang, Kimberly P , Lockwood, Megan M , Sanchez-Rodriguez, Alain , Williams, Jessica N , Turner, Amy S , Duarte-García, Alí , Sammaritano, Lisa R , Askanase, Anca , Bermas, Bonnie , Son, Mary Beth F. , Werth, Victoria P. , Chong, Benjamin F. , Izmirly, Peter , Kamen, Diane L. , Thomas, Asha, Azzam, Muayad , Bartels, Christie M. , Fava, Andrea , Figueroa‐Parra, Gabriel , Garg, Shivani , Cuéllar‐Gutiérrez, María C. , Kawtharany, Hassan , Mustafa, Reem A

Mayo Clinic

Arthritis Care & Research | November 3, 2025 | Volume: 78 | Issue: 7 | Pages: 815-839

10.1002/acr.25690 | PMID 41182321 Get It

Objective To provide evidence‐based and expert guidance for the treatment and management of non‐renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline. Methods Clinical questions for treatment and management of SLE were developed in the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were developed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess evidence quality and formulate recommendations. The Voting Panel achieved a consensus of ≥70% agreement on the direction (for or against) and strength (strong or conditional) of each recommendation. Results We present recommendations and ungraded, consensus‐based good practice statements for the treatment and management of SLE that are applicable to pediatric and adult patients. Recommendations emphasize uniform treatment with hydroxychloroquine, limiting duration of glucocorticoid use, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve and maintain control of SLE inflammation (remission or a low level of disease activity), reduce SLE‐related morbidity and mortality, and minimize medication‐related toxicities. Conclusion This guideline presents direction regarding treatment and management of SLE and provides a foundation for well‐informed, shared clinician–patient decision‐making. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each person with SLE.
Serum IgA isotypes are associated with percent emphysema, wall thickness and lung function decline
Pottinger, Tess D. , Buschur, Kristina L., Ortega, Victor E. , Bleecker, Eugene R., Meyers, Deborah A., Hoffman, Eric A. , Smith, Benjamin M. , Kiryluk, Krzysztof , Barr, R. Graham , Pottinger, Tess , Kiryluk, Krzysztof , Hoffman, Eric A , Liu, Zhonghua , Liu, Lili , Curtis, Jeffrey L. , Manichaikul, Ani , Rich, Stephen S. , Meyers, Deborah A. , Novák, Jan

Mayo Clinic

Thorax | August 22, 2025 | Volume: 80 | Issue: 11 | Pages: 829-837

10.1136/thorax-2025-222990 | PMID 40846486 Get It

Rationale Immunoglobulin A (IgA) deficiency, a rare, highly heritable trait, is associated with frequent pulmonary infections, emphysema, airway changes and low lung function; however, it is unclear if reduced IgA levels may affect lung structure and function. Methods Serum IgA, IgA1 and galactose-deficient IgA1 (Gd-IgA1) levels were measured in the population-based Multi-Ethnic Study on Atherosclerosis (MESA). The MESA Lung Study measured percent emphysema on cardiac CT and airway dimensions on chest CT, and performed spirometry. Regression models were evaluated after adjustment for demographic and CT factors. Mendelian randomisation (MR) analyses were conducted using genetic variants from the Trans-Omics for Precision Medicine (TOPMed) programme. A replication analysis was performed in the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS). Measurements and main results Among 5497 participants, lower log-normalised serum IgA levels were associated with greater percent emphysema (β=−0.084; 95% CI −0.14 to –0.026; p=0.005), which was confirmed on MR (β=−0.79; 95% CI −1.4 to –0.18; p=0.011). Greater log-normalised serum Gd-IgA1 levels were associated with airway wall thickness (β=0.0079; 95% CI 0.0017 to 0.014; p=0.012; n=2580) and decline in the forced expiratory volume in one second (FEV1) (β=−0.012; 95% CI −0.021 to –0.0036; p=0.0055; n=2778) and FEV1/forced vital capacity (FVC) ratio (β=−0.0028; 95% CI −0.0048 to –0.00084; p=0.0054; n=2778). Conclusion Lower serum IgA levels were associated with greater percent emphysema. Additionally, higher Gd-IgA1 levels were associated with airway wall thickness and lung function decline. These findings support a protective role of IgA in emphysema pathogenesis and possible deleterious role of Gd-IgA1 in airway diseases.
Association of Contrast Enhanced Dual Energy CT-derived Pulmonary Arterial Tree-to-Lung Ratio (ArtLR) With COPD
Newcomb, Nora , Dunn, Melissa S., Guo, J. , Comellas, A.P., Woodruff, P., Curtis, J.L., Hansel, Nadia N. , Han, M.K. , Hoffman, E.A., Hosseini, S., Orr, J., Dunn, M., Leininger, J., Gerard, Sarah E. , Comellas, A.P., Jacob, Mathews , schroeder, J., Curtis, J.L., Reinhardt, Joseph M. , Hermann, E.A. , Barr, R. Graham , Smith, Benjamin M. , Hoffman, E.A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5007-A5007

10.1164/ajrccm.2025.211.abstracts.a5007 Get It

Abstract RATIONALE: Airway-to-lung ratio (AirLR), calculated as the mean of airway lumen diameters at standard anatomic locations divided by the cube-root of total lung volume, is associated with COPD risk regardless of smoking status, and we have previously shown an association between total-pulmonary-vascular-volume-to-lung-size relationship with AirLR. [PMCID: PMC11284327] Using dual energy computed tomography (DECT), we recently developed a deep learning-based algorithm for pulmonary arterial segmentation to compute pulmonary-arterial-to-lung ratio (ArtLR) which correlated significantly with AirLR and markers COPD. Here we automate image processing in a larger cohort to estimate ArtLR, introduce an alternative ArtLR standardization and correlate it to COPD-related measures of lung structure and function. METHODS: Using a SPIROMICS sub-cohort (110 participants), imaged via contrast enhanced DECT at functional residual capacity (FRC), an automatic deep learning pipeline segmented the arteries from the pulmonary vascular tree. Another pipeline automatically extracted the centerlines and calculated average arterial segment diameters. A paired non-contrast total lung capacity (TLC) scan was registered to the DECT FRC scan to transfer airway segment labels from the TLC to FRC domain. AirLR was calculated as the mean of airway lumen diameters at standard anatomic locations (trachea-to-subsegments) divided by cube root of lung volume [TLC or FRC]. A simple Long Short-Term Memory (LSTM) network was used to find corresponding anatomic arterial segments. Associations between ArtLR and %Emphysema, AirLR, pre- and post-bronchodilator FEV1/FVC, and a texture-based (AMFM) measure of %broncho-vascular bundles was assessed using linear regression to adjust for age, sex and BMI. RESULTS: In adjusted analyses, a 1-SD decrement in ArtLR-TLC was associated with 4.198 units increase in %Emphysema-910 (95%CI: 1.360-7.037; p = 0.0041), and 0.8198 units decrease in %Bronchovascular (95%CI: 0.5037-1.136; p &lt; 0.0001). A 1-SD increment in ArtLR-TLC was associated with 0.2515 SD increase in AirLR-Outer (95%CI: 0.04947SD-0.4536SD; p = 0.0152), and 0.02083 units increase in PreBronch-FEV1FVC (95%CI: 0.001814-0.03984; p = 0.0321). Sex and BMI show significant associations with ArtLR-TLC, where female is associated with 1.068 SD decrease in ArtLR, and a unit increase in BMI is associated with 0.05788 SD increase in ArtLR (both p-values &lt; 0.0001), and age was not association with ArtLR. CONCLUSIONS: An automated pipeline for pulmonary arterial tree segmentation and standardization from contrast enhanced DECT FRC scans demonstrates a significant relationship between ArtLR and AirLR as well as between ArtLR and %emphysema, and FEV1/FVC. A standardized method of arterial tree size assessment provides for expanded exploration of vascular vs airway disease etiologies.
Association of a Novel Index of Early-life Growth Conditions With Chronic Obstructive Pulmonary Disease Phenotype and Prognosis
Alter, M J, Debban, Catherine L., Goldman-Pham, R. , Bleecker, Eugene R. , Christenson, Stephanie A. , Cooper, C.B., Martinez, F.J., Meyers, D.A., Ortega, Victor E. , Paine, Robert , Rennard, S.I., Woodruff, P., Investigators, for the Watch the Spot, Christenson, Stephanie A , Alter, M., Barr, R. Graham , Barjaktarević, Igor , Cooper, C.B. , Couper, David , Lovinsky‐Desir, Stephanie , Han, Mingyuan , Martinez, F.J., Meyers, D.A., Rennard, S.I., Manichaikul, Ani , Smith, Benjamin M.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5005-A5005

10.1164/ajrccm.2025.211.abstracts.a5005 Get It

Abstract Rationale Chronic obstructive pulmonary disease (COPD) manifests later in life and is a leading cause of death worldwide. While smoking-related lung pathology is a long-recognized COPD etiotype, emerging evidence suggests that early-life growth conditions also play an important role. A recently-developed index of early-life growth conditions – the difference between attained height and genotype-predicted height (height-GaP) – has been validated against prospectevely ascertained adverse early-life growth conditions. This study used height-GaP to evaluate the association of early-life growth conditions with COPD phenotype and prognosis later in life. Methods Among current and former smokers with spirometry-defined COPD in the SubPopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS), we computed height-GaP as the difference between attained height and genotype-predicted height. Regression models were fit for respiratory mortality (defined by primary diagnostic code), dyspnea prevalence (Medical Research Council dyspnea rating &gt;1), chronic bronchitis prevalence, airflow obstruction severity as quantified by FEV1Q, and functional capacity (six-minute walk distance), adjusting for age, age2, sex, race-ethnicity, genotype-predicted height, cigarette smoking status and pack-years. Sensitivity analyses accounted for competing risks of death (Fine-Gray subdistribution hazard model) and accounted for later-life height loss (restricting sample to participants under 50 years). Results Among 1,258 participants with COPD (mean±SD age: 65.4±8.0 years, 42.4% female, mean±SD pack-years: 53.6±28.2, mean±SD FEV1%: 63.3±23.9%), there were 202 respiratory deaths over a median 7.5 years of follow-up (Figure). Larger height-GaP deficit was associated with higher respiratory mortality (adjusted hazard ratio [aHR]: 1.30 [95%CI: 1.12 to 1.50] per 1-SD increment in height-GaP deficit). This association remained significant after accounting for competing events (p=0.001) and when restricted to participants under 50 years (p=0.032). Larger height-GaP deficit was associated with higher dyspnea prevalence (adjusted prevalence ratio: 1.13 [95%CI: 1.02 to 1.25] per 1-SD increment in height-GaP deficit), lower FEV1Q (adjusted mean difference: -0.37 [95%CI: -0.45 to -0.29] per 1-SD height-GaP deficit), and shorter 6-minute walk (adjusted mean difference: -16.6 m [95%CI: -23.1 m to -10.0 m] per 1-SD increment in height-GaP deficit), but not chronic bronchitis or CAT score ≥10 (p&gt;0.05 for each). Conclusions Among current and former smokers with COPD, a quantitative index of early-life conditions was associated with higher respiratory mortality, in addition to dyspnea, airflow obstruction severity and reduced functional capacity. These results suggest that early-life growth conditions may influence COPD phenotype and prognosis later in life.